Table 3.

Multivariable Regression Analysis for Changes in the Lipoprotein-Associated Phospholipase A₂ Level

Characteristic	β ± SE	P
Statin treatment groupa	−0.0829 ± 0.0317	<.001
Change in LDL cholesterol level	0.0781 ± 0.0526	.1375
Current PI use	−0.0312 ± 0.0274	.2552
CD8+CD38+HLA-DR+ ≥19%b	−0.0382 ± 0.0342	.2644
Age >40 yc	−0.0004 ± 0.0322	.9912
Male sex	−0.0037 ± 0.0333	.9105
Nadir CD4+ T-cell count <100 cells/µLd	0.0619 ± 0.0302	.04
HIV type 1 RNA load <50 copies/mLe	0.0123 ± 0.0344	.7201

R² = 0.1660.

Abbreviations: HLA, human leukocyte antigen; LDL, low-density lipoprotein; PI, protease inhibitor; SE, standard error.

^a Statin treatment group vs placebo group.

^b Percentage of CD8⁺ T cells expressing CD38 and HLA-DR antigens ≥19% vs <19%.

^c Age >40 vs ≤40 years.

^d Nadir CD4⁺ T-cell count <100 vs ≥100 cells/µL.

^e HIV type 1 RNA load <50 vs >50 copies/mL.